{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,25]],"date-time":"2026-01-25T08:39:07Z","timestamp":1769330347040,"version":"3.49.0"},"reference-count":58,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2013,5,1]],"date-time":"2013-05-01T00:00:00Z","timestamp":1367366400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,5,1]],"date-time":"2013-05-01T00:00:00Z","timestamp":1367366400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Leukemia Research"],"published-print":{"date-parts":[[2013,5]]},"DOI":"10.1016\/j.leukres.2013.01.006","type":"journal-article","created":{"date-parts":[[2013,2,4]],"date-time":"2013-02-04T22:30:21Z","timestamp":1360017021000},"page":"487-495","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["Considerations for early switch to nilotinib or dasatinib in patients with chronic myeloid leukemia with inadequate response to first-line imatinib"],"prefix":"10.1016","volume":"37","author":[{"given":"Alfonso","family":"Quint\u00e1s-Cardama","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elias J.","family":"Jabbour","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.leukres.2013.01.006_bib0005","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1056\/NEJMoa022457","article-title":"Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia","volume":"348","author":"O\u2019Brien","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.leukres.2013.01.006_bib0010","first-page":"1126","article-title":"International Randomized Study of Interferon vs STI571 (IRIS) 8-year follow up: sustained survival and low risk for progression or events in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) treated with imatinib","volume":"114","author":"Deininger","year":"2009","journal-title":"Blood (ASH Annu Meet Abstr)"},{"key":"10.1016\/j.leukres.2013.01.006_bib0015","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1056\/NEJMoa062867","article-title":"Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia","volume":"355","author":"Druker","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.leukres.2013.01.006_bib0020","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1038\/leu.2009.38","article-title":"Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia","volume":"23","author":"Hochhaus","year":"2009","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2013.01.006_bib0025","doi-asserted-by":"crossref","first-page":"6041","DOI":"10.1200\/JCO.2009.25.0779","article-title":"Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet","volume":"27","author":"Baccarani","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.leukres.2013.01.006_bib0030","unstructured":"Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae) for Chronic Myelogenous Leukemia V.3.2013. \u00a9 National Comprehensive Cancer Network, Inc. 2013. All rights reserved. Accessed January 9, 2013. To view the most recent and complete version of the guideline, go online to www.nccn.org. NATIONAL COMPREHENSIVE CANCER NETWORK\u00ae, NCCN\u00ae, NCCN GUIDELINES\u00ae, and all other NCCN Content are trademarks owned by the National Comprehensive Cancer Network, Inc."},{"issue":"Suppl. 2","key":"10.1016\/j.leukres.2013.01.006_bib0035","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.6004\/jnccn.2011.0125","article-title":"NCCN task force report: tyrosine kinase inhibitor therapy selection in the management of patients with chronic myelogenous leukemia","volume":"9","author":"O\u2019Brien","year":"2011","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.leukres.2013.01.006_bib0040","unstructured":"Iclusig (Ponatinib) [Prescribing Information]. Cambridge, MA: ARIAD Pharmaceuticals, Inc., 2012."},{"key":"10.1016\/j.leukres.2013.01.006_bib0045","doi-asserted-by":"crossref","DOI":"10.1002\/cncr.26568","article-title":"Very long-term follow-up results of imatinib mesylate therapy in chronic phase chronic myeloid leukemia after failure of interferon alpha therapy","author":"Kantarjian","year":"2012","journal-title":"Cancer"},{"key":"10.1016\/j.leukres.2013.01.006_bib0050","doi-asserted-by":"crossref","first-page":"3758","DOI":"10.1182\/blood-2010-03-273979","article-title":"Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the International Randomized Study of Interferon and STI571 (IRIS)","volume":"116","author":"Hughes","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2013.01.006_bib0055","doi-asserted-by":"crossref","first-page":"6315","DOI":"10.1182\/blood-2008-07-166694","article-title":"Delayed achievement of cytogenetic and molecular response is associated with increased risk of progression among patients with chronic myeloid leukemia in early chronic phase receiving high-dose or standard-dose imatinib therapy","volume":"113","author":"Quintas-Cardama","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2013.01.006_bib0060","doi-asserted-by":"crossref","first-page":"4437","DOI":"10.1182\/blood-2008-06-162388","article-title":"European LeukemiaNet criteria for failure or suboptimal response reliably identify patients with CML in early chronic phase treated with imatinib whose eventual outcome is poor","volume":"112","author":"Marin","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2013.01.006_bib0065","doi-asserted-by":"crossref","DOI":"10.1007\/s12185-012-1093-y","article-title":"Comprehensive therapeutic outcomes of frontline imatinib mesylate in newly diagnosed chronic phase chronic myeloid leukemia patients in Korea: feasibility assessment of current ELN recommendation","author":"Kim","year":"2012","journal-title":"Int J Hematol"},{"key":"10.1016\/j.leukres.2013.01.006_bib0070","doi-asserted-by":"crossref","first-page":"2401","DOI":"10.1038\/sj.leu.2403158","article-title":"Imatinib produces significantly superior molecular responses compared to interferon alfa plus cytarabine in patients with newly diagnosed chronic myeloid leukemia in chronic phase","volume":"17","author":"Branford","year":"2003","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2013.01.006_bib0075","first-page":"451","article-title":"Upfront imatinib therapy in CML patients with rapid switching to nilotinib for failure to achieve molecular targets or intolerance achieves high overall rates of molecular response and a low risk of progression \u2013 an update of the TIDEL-II trial","volume":"118","author":"Yeung","year":"2011","journal-title":"Blood (ASH Annu Meet Abstr)"},{"key":"10.1016\/j.leukres.2013.01.006_bib0080","first-page":"3784","article-title":"Kinetics of molecular response with different tyrosine kinase inhibitors (TKI) used as frontline therapy in chronic myeloid leukemia-chronic phase (CML CP)","volume":"118","author":"Naqvi","year":"2011","journal-title":"Blood (ASH Annu Meet Abstr)"},{"key":"10.1016\/j.leukres.2013.01.006_bib0085","first-page":"783","article-title":"Molecular and cytogenetic response after 3 months of imatinib treatment is predictive for the risk of disease progression and death in newly diagnosed chronic myeloid leukemia patients \u2013 a follow-up analysis of the German CML Study IV","volume":"118","author":"Hanfstein","year":"2011","journal-title":"Blood (ASH Annu Meet Abstr)"},{"key":"10.1016\/j.leukres.2013.01.006_bib0090","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1200\/JCO.2011.38.6565","article-title":"Assessment of BCR-ABL1 transcript levels at 3 months is the only requirement for predicting outcome for patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors","volume":"30","author":"Marin","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.leukres.2013.01.006_bib0095","doi-asserted-by":"crossref","first-page":"3709","DOI":"10.1002\/cncr.24418","article-title":"Significance of suboptimal response to imatinib, as defined by the European LeukemiaNet, in the long-term outcome of patients with early chronic myeloid leukemia in chronic phase","volume":"115","author":"Alvarado","year":"2009","journal-title":"Cancer"},{"key":"10.1016\/j.leukres.2013.01.006_bib0100","first-page":"2196","article-title":"Chronic myeloid leukemia (CML) patients with suboptimal \u201cresponse to imatinib (IM) according to European LeukemiaNet criteria have a poorer outcome with respect to optimal\u201d responders: a GIMEMA CML working party analysis","volume":"114","author":"Castagnetti","year":"2009","journal-title":"ASH Annu Meet Abstr"},{"issue":"s1","key":"10.1016\/j.leukres.2013.01.006_bib0105","first-page":"76","article-title":"Molecular response kinetics and BCR-ABL reductions in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) receiving dasatinib vs imatinib: DASISION 3-year follow-up","volume":"97","author":"Hochhaus","year":"2012","journal-title":"Haematologica"},{"issue":"s1","key":"10.1016\/j.leukres.2013.01.006_bib0110","first-page":"237","article-title":"Early BCR-ABL transcript levels predict future molecular response and long-term outcomes in newly diagnosed patients with chronic myeloid leukemia in chronic phase: analysis of ENESTnd 3-year data","volume":"97","author":"Hochhaus","year":"2012","journal-title":"Haematologica"},{"key":"10.1016\/j.leukres.2013.01.006_bib0115","doi-asserted-by":"crossref","first-page":"4541","DOI":"10.1182\/blood-2011-04-348110","article-title":"The achievement of an early complete cytogenetic response is a major determinant for outcome in patients with early chronic phase chronic myeloid leukemia treated with tyrosine kinase inhibitors","volume":"118","author":"Jabbour","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2013.01.006_bib0120","first-page":"785","article-title":"The predictive value of early molecular response in chronic phase CML patients treated with dasatinib first line therapy","volume":"118","author":"Marin","year":"2011","journal-title":"Blood (ASH Annu Meet Abstr)"},{"key":"10.1016\/j.leukres.2013.01.006_bib0125","first-page":"1684","article-title":"The month three major molecular response in chronic phase chronic myeloid leukemia on imatinib 400, nilotinib and dasatinib is a major prognostic factor for failure-free and progression-free survival","volume":"118","author":"Nicolini","year":"2011","journal-title":"Blood (ASH Annu Meet Abstr)"},{"key":"10.1016\/j.leukres.2013.01.006_bib0130","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1200\/JCO.2011.41.1090","article-title":"Classification of patients with chronic myeloid leukemia on basis of BCR-ABL transcript level at 3 months fails to identify patients with low organic cation transporter-1 activity destined to have poor imatinib response","volume":"30","author":"White","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.leukres.2013.01.006_bib0135","doi-asserted-by":"crossref","first-page":"2381","DOI":"10.1200\/JCO.2009.26.3087","article-title":"Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib","volume":"28","author":"Marin","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.leukres.2013.01.006_bib0140","doi-asserted-by":"crossref","first-page":"5401","DOI":"10.1182\/blood-2008-12-196543","article-title":"Prevalence, determinants, and outcomes of nonadherence to imatinib therapy in patients with chronic myeloid leukemia: the ADAGIO study","volume":"113","author":"Noens","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2013.01.006_bib0145","unstructured":"Tasigna (Nilotinib) [Prescribing Information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation, 2011."},{"key":"10.1016\/j.leukres.2013.01.006_bib0150","unstructured":"Sprycel (Dasatinib) [Prescribing Information]. Princeton, NJ: Bristol-Myers Squibb, 2011."},{"key":"10.1016\/j.leukres.2013.01.006_bib0155","unstructured":"Bosulif (Bosutinib) [Prescribing Information]. New York, NY: Pfizer Labs, 2012."},{"key":"10.1016\/j.leukres.2013.01.006_bib0160","first-page":"3780","article-title":"Impact of second-generation tyrosine kinase inhibitors as second line treatment for patients with chronic myeloid leukemia","volume":"118","author":"Garcia-Gutierrez","year":"2011","journal-title":"Blood (ASH Annu Meet Abstr)"},{"key":"10.1016\/j.leukres.2013.01.006_bib0165","first-page":"2765","article-title":"Efficacy of nilotinib versus high-dose imatinib in early chronic phase CML patients who have suboptimal molecular responses to standard-dose imatinib (RE-NICE multicenter study)","volume":"118","author":"Goh","year":"2011","journal-title":"Blood (ASH Annu Meet Abstr)"},{"key":"10.1016\/j.leukres.2013.01.006_bib0170","doi-asserted-by":"crossref","first-page":"5143","DOI":"10.1182\/blood-2006-11-056028","article-title":"Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia after failure of first-line imatinib: a randomized phase 2 trial","volume":"109","author":"Kantarjian","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2013.01.006_bib0175","doi-asserted-by":"crossref","first-page":"4136","DOI":"10.1002\/cncr.24504","article-title":"Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia resistant to imatinib at a dose of 400 to 600 milligrams daily: two-year follow-up of a randomized phase 2 study (START-R)","volume":"115","author":"Kantarjian","year":"2009","journal-title":"Cancer"},{"key":"10.1016\/j.leukres.2013.01.006_bib0180","first-page":"3771","article-title":"Early switch to nilotinib does not overcome the adverse outcome for CML patients failing to achieve early molecular response on imatinib, despite excellent overall outcomes in the TIDEL II trial","volume":"120","author":"Yeung","year":"2012","journal-title":"Blood (ASH Annu Meet Abstr)"},{"key":"10.1016\/j.leukres.2013.01.006_bib0185","doi-asserted-by":"crossref","first-page":"2912","DOI":"10.1002\/cncr.24325","article-title":"Dasatinib early intervention after cytogenetic or hematologic resistance to imatinib in patients with chronic myeloid leukemia","volume":"115","author":"Quintas-Cardama","year":"2009","journal-title":"Cancer"},{"key":"10.1016\/j.leukres.2013.01.006_bib0190","first-page":"331","article-title":"The initial molecular response of chronic phase CML patients treated with second generation ABL inhibitor therapy after imatinib failure can predict inadequate response and provide indications for rational mutation screening","volume":"112","author":"Branford","year":"2008","journal-title":"Blood (ASH Annu Meet Abstr)"},{"key":"10.1016\/j.leukres.2013.01.006_bib0195","unstructured":"Gleevec (Imatinib) [Prescribing Information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation, 2011."},{"key":"10.1016\/j.leukres.2013.01.006_bib0200","doi-asserted-by":"crossref","first-page":"5600","DOI":"10.1182\/blood-2010-11-318949","article-title":"Minimal cross-intolerance with nilotinib in patients with chronic myeloid leukemia in chronic or accelerated phase who are intolerant to imatinib","volume":"117","author":"Cortes","year":"2011","journal-title":"Blood"},{"issue":"Suppl.","key":"10.1016\/j.leukres.2013.01.006_bib0205","doi-asserted-by":"crossref","first-page":"7015","DOI":"10.1200\/jco.2008.26.15_suppl.7015","article-title":"Dasatinib lack of cross intolerance to imatinib in patients (pts) with chronic myelogenous leukemia chronic phase (CML-CP) intolerant to imatinib: a retrospective analysis of safety","volume":"26","author":"Khoury","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.leukres.2013.01.006_bib0210","doi-asserted-by":"crossref","first-page":"4567","DOI":"10.1182\/blood-2011-05-355594","article-title":"Safety and efficacy of bosutinib (SKI-606) in chronic phase Philadelphia chromosome-positive CML patients with resistance or intolerance to imatinib","volume":"118","author":"Cortes","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2013.01.006_bib0215","first-page":"3","article-title":"How cancer treatment benefits from the industry's input","volume":"5","author":"Fogarty","year":"2008","journal-title":"Oncol Times"},{"key":"10.1016\/j.leukres.2013.01.006_bib0220","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1002\/cncr.22523","article-title":"Diagnosis and management of chronic myeloid leukemia: a survey of American and European practice patterns","volume":"109","author":"Kantarjian","year":"2007","journal-title":"Cancer"},{"key":"10.1016\/j.leukres.2013.01.006_bib0225","series-title":"Presented at International Society of Pharmacoeconomics and Outcomes Research (ISPOR) 16th Annual International Meeting","article-title":"Resource utilization and perceptions of major molecular response in chronic myeloid leukemia (CML): results of a Delphi panel study","author":"Quintas-Cardama","year":"2011"},{"key":"10.1016\/j.leukres.2013.01.006_bib0230","doi-asserted-by":"crossref","first-page":"4022","DOI":"10.1182\/blood-2007-10-116475","article-title":"Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study","volume":"111","author":"Larson","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2013.01.006_bib0235","doi-asserted-by":"crossref","first-page":"207","DOI":"10.7326\/0003-4819-131-3-199908030-00008","article-title":"Chronic myelogenous leukemia: biology and therapy","volume":"131","author":"Faderl","year":"1999","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.leukres.2013.01.006_bib0240","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1002\/ajh.23238","article-title":"Early landmark analysis of imatinib treatment in CML chronic phase: less than 10% BCR-ABL by FISH at 3 months associated with improved long-term clinical outcome","volume":"87","author":"Ohm","year":"2012","journal-title":"Am J Hematol"},{"key":"10.1016\/j.leukres.2013.01.006_bib0245","first-page":"3783","article-title":"Complete cytogenetic response after 3 months is a very early indicator of good response to imatinib as front-line treatment in chronic myelogenous leukemia","volume":"118","author":"Latagliata","year":"2011","journal-title":"Blood (ASH Annu Meet Abstr)"},{"key":"10.1016\/j.leukres.2013.01.006_bib0250","first-page":"2767","volume":"118","author":"Hochhaus","year":"2011","journal-title":"Blood (ASH Annu Meet Abstr)"},{"key":"10.1016\/j.leukres.2013.01.006_bib0255","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1182\/blood-2010-03-277152","article-title":"Nilotinib is effective in patients with chronic myeloid leukemia in chronic phase after imatinib resistance or intolerance: 24-month follow-up results","volume":"117","author":"Kantarjian","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2013.01.006_bib0260","first-page":"3770","article-title":"Nilotinib in imatinib-resistant or -intolerant patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP): 48-month follow-up results of a phase 2 study","volume":"118","author":"Le Coutre","year":"2011","journal-title":"Blood (ASH Annu Meet Abstr)"},{"key":"10.1016\/j.leukres.2013.01.006_bib0265","first-page":"2771","article-title":"Effect of nilotinib (NIL) on molecular response in chronic myelogenous leukemia \u2013 chronic phase (CML-CP) patients (pts) with a suboptimal molecular response to imatinib (IM) \u2013 ENABL study update","volume":"118","author":"Ailawadhi","year":"2011","journal-title":"Blood (ASH Annu Meet Abstr)"},{"key":"10.1016\/j.leukres.2013.01.006_bib0270","first-page":"114","volume":"118","author":"Hochhaus","year":"2011","journal-title":"Blood (ASH Annu Meet Abstr)"},{"key":"10.1016\/j.leukres.2013.01.006_bib0275","first-page":"606","volume":"118","author":"Hughes","year":"2011","journal-title":"Blood (ASH Annu Meet Abstr)"},{"key":"10.1016\/j.leukres.2013.01.006_bib0280","doi-asserted-by":"crossref","first-page":"2303","DOI":"10.1182\/blood-2006-09-047266","article-title":"Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy","volume":"109","author":"Hochhaus","year":"2007","journal-title":"Blood"},{"issue":"Suppl.","key":"10.1016\/j.leukres.2013.01.006_bib0285","doi-asserted-by":"crossref","first-page":"6512","DOI":"10.1200\/jco.2011.29.15_suppl.6512","article-title":"Five-year follow-up of patients with imatinib-resistant or -intolerant chronic-phase chronic myeloid leukemia (CML-CP) receiving dasatinib","volume":"29","author":"Shah","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.leukres.2013.01.006_bib0290","doi-asserted-by":"crossref","first-page":"3204","DOI":"10.1200\/JCO.2007.14.9260","article-title":"Intermittent target inhibition with dasatinib 100mg once daily preserves efficacy and improves tolerability in imatinib-resistant and -intolerant chronic-phase chronic myeloid leukemia","volume":"26","author":"Shah","year":"2008","journal-title":"J Clin Oncol"}],"container-title":["Leukemia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212613000209?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212613000209?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T00:57:50Z","timestamp":1758934670000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0145212613000209"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,5]]},"references-count":58,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2013,5]]}},"alternative-id":["S0145212613000209"],"URL":"https:\/\/doi.org\/10.1016\/j.leukres.2013.01.006","relation":{},"ISSN":["0145-2126"],"issn-type":[{"value":"0145-2126","type":"print"}],"subject":[],"published":{"date-parts":[[2013,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Considerations for early switch to nilotinib or dasatinib in patients with chronic myeloid leukemia with inadequate response to first-line imatinib","name":"articletitle","label":"Article Title"},{"value":"Leukemia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.leukres.2013.01.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}